PTK2 and non-small cell lung carcinoma: Consistent with these pathological features, Fu et al. (2015) found that in NSCLC cells, ENO1 could enhance the proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and glycolytic capacity of tumor cells by activating the FAK/PI3K/AKT pathway.